^
Association details:
| Biomarker: | EGFR T790M negative |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Ameile (aumolertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and Safety of Aumolertinib as Second- Or Third-Line Therapy in EGFR T790M Negative/Unknown Non-small Cell Lung Cancer
Published date:
08/08/2023
Excerpt:
In the brain metastases subgroup (n=8), the mPFS was 10.6 months, ORR was 25% and DCR was 88%. Among 14 pts who received third-line aumolertinib treatment, the mPFS was 6.3 months, ORR was 0% and DCR was 79% (Efficacy; Table)...Aumolertinib showed promising antitumor activity with manageable toxicity as second- and third-line therapy in EGFR T790M-negative/unknown NSCLC with or without brain metastases.
